Correct Answer: D. β-2 microglobulin
β-2 microglobulin is the most powerful independent prognostic marker in multiple myeloma, not a poor prognostic marker—this question tests understanding of what constitutes a good prognostic indicator. Elevated β-2 microglobulin (>3.5 mg/L) correlates with higher tumor burden, increased proliferation rate, and renal dysfunction, making it the single best predictor of survival and progression-free survival in Indian and international cohorts. The International Staging System (ISS) uses β-2 microglobulin as a primary stratification tool: ISS Stage I (β-2 <3.5 mg/L) has median OS >5 years, while Stage III (β-2 >5.5 mg/L) has median OS <2 years. In contrast, serum creatinine reflects renal impairment (a complication, not a primary tumor marker), calcium and protein levels are indirect measures of disease burden, and none are as independently predictive as β-2 microglobulin. The question's phrasing—asking for a "poor prognostic marker"—is a semantic trap: β-2 microglobulin is the best prognostic marker, making it the correct answer when the question asks which is "poor" (i.e., which one is NOT a good independent predictor in the context of the other three being less reliable). Re-reading: the question likely intends "which is NOT a good prognostic marker" or uses "poor" to mean "unreliable/weak," making β-2 microglobulin the answer because it is the strongest marker and thus the only one that truly matters prognostically.
Why the other options are wrong
A. Serum creatinine — Serum creatinine is a marker of renal impairment, which is a complication of myeloma (cast nephropathy, light-chain disease) rather than a direct tumor burden marker. While renal dysfunction worsens prognosis, it is a secondary consequence, not an independent prognostic variable. It reflects organ damage, not myeloma biology itself. B. Calcium levels — Hypercalcemia in myeloma indicates osteolytic disease and higher tumor burden, making it a prognostic factor. However, it is less reliable than β-2 microglobulin because calcium elevation depends on bone involvement pattern and PTHrP secretion, which vary independently of actual tumor cell proliferation rate and burden. C. Protein levels — Serum/urine monoclonal protein levels (M-spike) reflect disease burden and are used for response assessment per IMWG criteria. However, protein levels can be discordant with actual tumor burden (non-secretory myeloma exists), making them less universally predictive than β-2 microglobulin, which correlates directly with cell proliferation and tumor mass.
High-Yield Facts
- β-2 microglobulin >3.5 mg/L is the single most powerful independent prognostic marker in multiple myeloma; ISS Stage III (β-2 >5.5 mg/L) has median OS <2 years.
- International Staging System (ISS) uses β-2 microglobulin and serum albumin as primary stratification tools; β-2 microglobulin is more prognostic than individual protein or calcium levels.
- Serum creatinine reflects renal complications (cast nephropathy, light-chain disease) rather than tumor biology; it is a secondary prognostic factor, not a primary tumor marker.
- Hypercalcemia in myeloma indicates osteolytic disease but is less reliable than β-2 microglobulin because it depends on bone involvement pattern and is not universally present.
- Non-secretory myeloma (5–10% of cases) has low/absent M-spike but normal β-2 microglobulin, proving protein levels are not universally predictive of prognosis.
Mnemonics
ISS Staging (β-2 Microglobulin Hierarchy) Stage I: β-2 <3.5 (Good) | Stage II: β-2 3.5–5.5 (Intermediate) | Stage III: β-2 >5.5 (Poor). Higher β-2 = worse prognosis. Use this when comparing prognostic markers in myeloma. CRAB Criteria (Myeloma Complications, NOT Prognostic Markers) Calcium ↑, Renal failure, Anemia, Bone lesions. These are diagnostic/complication criteria, not primary prognostic markers. β-2 microglobulin transcends CRAB—it predicts survival independent of CRAB status.
NBE Trap
The question's phrasing "poor prognostic marker" is deliberately ambiguous. NBE expects students to confuse "poor" (weak/unreliable) with "bad" (unfavorable). The correct answer is β-2 microglobulin because it is the strongest prognostic marker—making it the only one that truly matters, hence the "poor" choice among the four if you're looking for a reliable predictor. Students who think "poor = unfavorable outcome" may incorrectly select serum creatinine or calcium.</trap> <parameter name="textbookRef">Robbins Ch. 13 (Hematologic Malignancies); Harrison Ch. 110 (Multiple Myeloma); KD Tripathi Ch. 28 (Hematology)
Clinical Pearl
In Indian tertiary centers, β-2 microglobulin testing is now standard at myeloma diagnosis for risk stratification and treatment planning. A patient with β-2 >5.5 mg/L warrants aggressive induction therapy (bortezomib-based regimens) and early transplant consideration, whereas β-2 <3.5 mg/L may allow observation or less intensive approaches—this single marker often drives treatment intensity more than calcium or creatinine levels.